tetano
Editor, Senior Moderator
Am J Trop Med Hyg
. 2020 Jun 17;tpmd201594.
doi: 10.4269/ajtmh.20-1594. Online ahead of print.
SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
Ji Yeun Kim[SUP] 1 [/SUP], Ji-Soo Kwon[SUP] 2 [/SUP], Seongman Bae[SUP] 1 [/SUP], Hye Hee Cha[SUP] 1 [/SUP], Joon Seo Lim[SUP] 3 [/SUP], Min-Chul Kim[SUP] 4 [/SUP], Jin-Won Chung[SUP] 4 [/SUP], Se Yoon Park[SUP] 5 [/SUP], Myung Jin Lee[SUP] 6 [/SUP], Baek-Nam Kim[SUP] 6 [/SUP], Jiwon Jung[SUP] 1 [/SUP], Min-Jae Kim[SUP] 1 [/SUP], Eui-Cheol Shin[SUP] 2 [/SUP], Sung-Han Kim[SUP] 1 [/SUP]
Affiliations
Abstract
Data on the longevity of humoral and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with coronavirus disease 2019 (COVID-19) are limited. We evaluated the detailed kinetics of antibody and T-cell responses at the acute, convalescent, and post-convalescent phases in COVID-19 patients with a wide range of severity. We enrolled patients with COVID-19 prospectively from four hospitals and one community treatment center between February 2020 and January 2021. symptom severity was classified as mild, moderate, or severe/critical. Patient blood samples were collected at 1 week (acute), 1 month (convalescent), and 2 months after symptom onset (post-convalescent). Human SARS-CoV-2 IgG and IgM antibodies were measured using in-house-developed ELISA. The SARS-CoV-2-specific T-cell responses against overlapping peptides of spike proteins and nucleoprotein were measured by interferon-γ enzyme-linked immunospot assays. Twenty-five COVID-19 patients were analyzed (mild, n = 5; moderate, n = 9; severe/critical, n = 11). IgM and IgG antibody responses peaked at 1 month after symptom onset and decreased at 2 months. IgG response levels were significantly greater in the severe/critical group compared with other groups. Interferon-γ-producing T-cell responses increased between 1 week and 1 month after symptom onset, and had a trend toward decreasing at 2 months, but did not show significant differences according to severity. Our data indicate that SARS-CoV-2-specific antibody responses were greater in those with severe symptoms and waned after reaching a peak around 1 month after symptom onset. However, SARS-CoV-2-specific T-cell responses were not significantly different according to symptom severity, and decreased slowly during the post-convalescent phase.
. 2020 Jun 17;tpmd201594.
doi: 10.4269/ajtmh.20-1594. Online ahead of print.
SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
Ji Yeun Kim[SUP] 1 [/SUP], Ji-Soo Kwon[SUP] 2 [/SUP], Seongman Bae[SUP] 1 [/SUP], Hye Hee Cha[SUP] 1 [/SUP], Joon Seo Lim[SUP] 3 [/SUP], Min-Chul Kim[SUP] 4 [/SUP], Jin-Won Chung[SUP] 4 [/SUP], Se Yoon Park[SUP] 5 [/SUP], Myung Jin Lee[SUP] 6 [/SUP], Baek-Nam Kim[SUP] 6 [/SUP], Jiwon Jung[SUP] 1 [/SUP], Min-Jae Kim[SUP] 1 [/SUP], Eui-Cheol Shin[SUP] 2 [/SUP], Sung-Han Kim[SUP] 1 [/SUP]
Affiliations
- PMID: 34143752
- DOI: 10.4269/ajtmh.20-1594
Abstract
Data on the longevity of humoral and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with coronavirus disease 2019 (COVID-19) are limited. We evaluated the detailed kinetics of antibody and T-cell responses at the acute, convalescent, and post-convalescent phases in COVID-19 patients with a wide range of severity. We enrolled patients with COVID-19 prospectively from four hospitals and one community treatment center between February 2020 and January 2021. symptom severity was classified as mild, moderate, or severe/critical. Patient blood samples were collected at 1 week (acute), 1 month (convalescent), and 2 months after symptom onset (post-convalescent). Human SARS-CoV-2 IgG and IgM antibodies were measured using in-house-developed ELISA. The SARS-CoV-2-specific T-cell responses against overlapping peptides of spike proteins and nucleoprotein were measured by interferon-γ enzyme-linked immunospot assays. Twenty-five COVID-19 patients were analyzed (mild, n = 5; moderate, n = 9; severe/critical, n = 11). IgM and IgG antibody responses peaked at 1 month after symptom onset and decreased at 2 months. IgG response levels were significantly greater in the severe/critical group compared with other groups. Interferon-γ-producing T-cell responses increased between 1 week and 1 month after symptom onset, and had a trend toward decreasing at 2 months, but did not show significant differences according to severity. Our data indicate that SARS-CoV-2-specific antibody responses were greater in those with severe symptoms and waned after reaching a peak around 1 month after symptom onset. However, SARS-CoV-2-specific T-cell responses were not significantly different according to symptom severity, and decreased slowly during the post-convalescent phase.